sVCAM-1、sPECAM-1在慢性阻塞性肺疾病中的检测及临床意义

Detection and clinical significance of sVCAM-1 and sPECAM -1 in chronic obstructive pulmonary disease

目的探讨可溶性血管细胞间粘附分子-1(sVCAM-1)和可溶性血小板内皮细胞黏附分子-1(sPECAM-1)在慢性阻塞性肺疾病(COPD)发病中的作用。方法病例来自我院呼吸科住院和门诊病人,采用酶联免疫吸附测定法(ELISA)检测20例健康成人(对照组)、35例COPD急性加重期患者(COPD组)治疗前后血浆中sVCAM-1和sPECAM-1的水平。结果sVCAM-1在COPD治疗前组([10.94±5.26)nmol/L]明显高于治疗后组([8.32±4.24)nmol/L]及对照组([7.34±3.68)nmol/L],差异有统计学意义(q=2.24、2.75,P均<0.05),而治疗后组与对照组差异无统计学意义(q=0.75,P=0.455);sPECAM-1在COPD治疗后组([61.01±12.53)pmol/L]明显高于治疗前组([35.99±8.05)pmol/L]及对照组([43.11±10.41)pmol/L],差异有统计学意义(q=9.23、5.91,P均<0.001),且对照组亦显著高于治疗前组(q=2.35,P=0.021)。结论sVCAM-1在COPD急性加重期患者显著增高,提示sVCAM-1可作为判断COPD病情严重程度和疗效的指标;sPECAM-1在COPD治疗后显著增高,可能在COPD病程中起保护性作用。

Objective To explore the role of sVCAM-1 and sPECAM-1 of prethrombotic state mediator in patients with chronic obstructive pulmonary disease （COPD）. Methods To detect the levels of sVCAM-1 and sPECAM-1 in blood plasma of 20 cases with healthy（control group） and 35 cases with COPD group before treatment and post-treatment plasma with ELISA,respectively.Results The level of sVCAM-1 in before treatment group [（ 10.94±5.26）nmol/L] was significantly higher than those of post-treatment group [（8.32±4.24）nmol/L] and control group [（7.34±3.68）nmol/L] （q=2.24,2.75, both P〈0.001）and the difference of sVCAM-lbetween the post-treatment group and the control group was not significant （q= 0.75,P=0.455）.The level of sPECAM-1 in post-treatment group [（61.01±12.53）pmol/L] was significantly higher than those of before treatment group [（35.99±8.05）pmol/L] and control group [（43.11±10.41 ）pmol/L]（q=9.23,5.91, beth P〈0.001 ）,the level of control group was also obviously higher than the before treatment group （q=2.35 ,P=0.021 ）.Conclusions The levels of sVCAM-1 increase significantly during acute exacerbation stage of COP]） ,which may evaluate the curative effect of COPD. The significant increasing of sPECAM-1 in plasma of post-treatment group suggests that sPECAM-1 may be a protective factor during COPD.